Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose

Intensive Care Medicine

Volumn 32, Issue 7, 2006, Pages 1060-1065

  Isbister, Geoffrey K ^a,b   Friberg, Lena E ^c   Duffull, Stephen B ^c  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Citalopram; Clinical guidelines; Overdose; Pharmacokinetic pharmacodynamic modelling; Simulation; Toxicity

Indexed keywords

ACTIVATED CARBON; AMFEBUTAMONE; CITALOPRAM; DESIPRAMINE; DOSULEPIN; DOXEPIN; DOXYLAMINE; MIRTAZAPINE; MOCLOBEMIDE; OLANZAPINE; PERICIAZINE; PHENTERMINE; PROCHLORPERAZINE; PROMETHAZINE; PSEUDOEPHEDRINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER SIMULATION; DOSE TIME EFFECT RELATION; DRUG OVERDOSE; FEMALE; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; RR INTERVAL; TORSADE DES POINTES; TREATMENT OUTCOME; UNPLEASANT SENSATION; VOMITING;

ADOLESCENT; ADULT; AGED; CHARCOAL; CITALOPRAM; COMPUTER SIMULATION; FEMALE; GUIDELINES; GUIDELINES AS TOPIC; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OVERDOSE; SEROTONIN UPTAKE INHIBITORS;

EID: 33745452416     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-006-0183-9     Document Type: Article

References (21)

1. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42:277-285
2. Personne M, Sjöberg G, Persson H (1997) Citalopram overdose - review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35:237-240
3. Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, Thebault B, Funck F (2001) [Citalopram and Torsades de Pointes. A case report]. Arch Mal Coeur Vaiss 94:1021-1024
4. Tarabar AF, Hoffman RS, Nelson LS (2003) Citalopram overdose: Late presentation of Torsades de Pointes (TdP) with cardiac arrest [abstract]. J Toxicol Clin Toxicol 41:676
5. Ostrom M, Eriksson A, Thorson J, Spigset O (1996) Fatal overdose with citalopram. Lancet 348:339-340
6. Jonasson B, Saldeen T (2002) Citalopram in fatal poisoning cases. Forensic Sci Int 126:1-6
7. Chew DP, Allan RM, Aroney CN, Sheerin NJ (2005) National data elements for the clinical management of acute coronary syndromes. Med J Aust 182:S1-14
8. Bond GR (2002) The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med 39:273-286
9. Cooper GM, Le Couteur DG, Richardson D, Buckley NA (2005) A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM 98:655-660
10. Friberg LE, Isbister GK, Duffull SB (2006) Pharmacokinetic- pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 61:177-190
11. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF (2000) Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 50:263-268
12. Friberg LE, Isbister GK, Hackett LP, Duffull SB (2005) The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 32:571-605
13. Moss AJ (1999) The QT interval and torsade de pointes. Drug Saf 21:1:5-10
14. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ (2002) Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87:220-228
15. Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312:1-11
16. Balit CR, Isbister GK, Hackett LP, Whyte IM (2003) Quetiapine poisoning: a case series. Ann Emerg Med 42:751-758
17. Isbister GK, Balit CR (2003) Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 37:999-1002
18. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M (2002) QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282:H2356-H2363
19. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692
20. Kragh-Sorensen P, Overo KF, Petersen OL, Jensen K, Parnas W (1981) The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh) 48:53-60
21. Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ (2004) Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 27:1659-1669